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Clinical xeno-organ transplantation
The gap between the number of patients waiting
for various organ transplantations and the num-
ber of available grafts increases steadily. Xeno-
transplantation – the use of animal organs and
tissues for transplantation to man – may provide
a solution to this problem. Small series of xeno-
transplantations were performed already in the
1960's. In most cases, non-human primates
such as chimpanzees or baboons, were used as
source animals. In one case, a chimpanzee kid-
ney transplant functioned for nine months in a
young woman. The result is remarkable, con-
sidering the primitive immunosuppressive ther-
apy available in those days. In most cases, how-
ever, organs from non-human primates were
rejected within days (10). In a few cases, trans-
plantations of organs from pig or sheep were at-
tempted, but the function of these organs ceased
already during the operations. It became obvi-
ous that the immunological response was diffi-
cult to control, and that the greater the phyloge-
netic disparity between source animal and
recipient, the more aggressive was the rejection
response. When the donation of human organs
from cadaveric donors became established, the
interest for xenotransplantation temporarily
ceased.
The results with human organ transplantation
have gradually improved since, and more and
more patients are opting for a transplant. Wait-
ing times increase and patients waiting for life-
supporting organs such as livers, hearts and
lungs die on the waiting list. It has always been
especially difficult to find grafts for small chil-
dren in need for size-matched thoracic trans-
plants. In 1984, an American group therefore
attempted to transplant a baboon heart to a new-
born infant dying from congenital heart malfor-
mation (1). The transplantation was technically
successful, and for the first days the graft func-
tioned well. However, graft failure occurred af-
ter 20 days, probably due to rejection. The so-
called "Baby Fae case" was given great public
attention, and the ethics behind performing
such a highly experimental procedure on a dy-
ing child was intensively discussed.
Besides increasing the number of available
grafts, xenotransplants may also provide an ad-
vantage by being resistant to certain diseases
that tend to recur and destroy a human graft.
One such example is, that baboons are resistant
to human hepatitis B, a disease that inevitably
recurs after human liver transplantation. In
1992-1993, two cases of baboon-to-man liver
transplantation were performed in Pittsburgh,
USA (8). Both patients suffered from Hepatitis
B and were in those days not considered eligi-
ble for human liver transplantation. The first pa-
tient had initially a very promising course. He
was in hepatic coma at the time of transplanta-
tion. After 24 hours he could be taken off the
ventilator, and after five days he was back at the
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ward, eating and moving around. As could be
expected, several biochemical parameters
changed to a baboon profile, but this did not
seem to cause any problems, at least in the short
run. However, infectious complications devel-
oped and the patient died at day 70 in a cerebral
bleeding caused by an Aspergillus infection,
most probably related to the intense immuno-
suppression. The second patient survived for 26
days, but never regained consciousness or renal
function. In both cases, there was little
histopathological evidence of rejection in the
transplanted livers. 
Obviously, non-human primates offer the best
physiological compatibility, and the disease im-
munological barrier also seems more manage-
able. However, due to infectious risk considera-
tions, ethical concerns and the limited supply of
non-human primates, most groups today con-
sider the pig to be the most suitable species for
clinical xenotransplantation. One major prob-
lem is then that vascularized organs trans-
planted from pig to man undergo hyperacute re-
jection, a rapid immunological process that
destroys the transplanted organ within a few
hours. All humans have preformed antibodies
directed against pig-specific antigens mainly
the Gal-epitope. After revascularization of the
graft, these antibodies bind to the pig endothe-
lium and complement is activated. The process
leads to vascular damage, thrombosis and
bleeding and more or less immediate organ fail-
ure.  Prevention of hyperacute rejection re-
quires very intense pre-treatment of the recipi-
ent with antibody removal or complement
inhibition. Such pre-treatment was considered
far too risky for routine clinical use.  
In the beginning of the 1990's, a British group
produced transgenic pigs specifically designed
as source animals to man (7). These pigs carry
a human complement regulatory factor (e.g.
hDAF) and hyperacute rejection can thus be
avoided. Organs from such pigs have now been
transplanted to non-human primates, a model
that should mimic the immunological barrier
between pig and man. Transgenic pig hearts
and kidneys have provided life-supporting
function for up to a few months, but the later
stages of the rejection process are still difficult
to control. So far, livers from similar transgenic
pigs have in a few cases been used for extracor-
poreal perfusion in patients with acute liver
failure. The livers were then temporarily con-
nected to the patients circulation and seem to
have provided some detoxifying effects.
Whether they provided any immunological ad-
vantage compared to wild type pig livers has
been hard to judge in this model, and so far,
transgenic pig organs have not been trans-
planted as permanent grafts to man. During
2002 the development of Gal knock-out pigs
was reported. The hypothesis is that these or-
gans will cause a less intense rejection re-
sponse, but so far no data on primate studies are
available. 
Clinical xeno-cell transplantation
The majority of xenotransplantations per-
formed during the 1990's have been cellular
transplantations. In the beginning of 1990's, ten
patients at Huddinge University Hospital,
Stockholm, Sweden underwent transplantation
with porcine foetal pancreatic islets (5). The
study was performed in collaboration with the
Biomedical Centre in Uppsala, Sweden, and
proceeded with experimental studies showing
maturation and function of the foetal beta-cells
in adult recipients. The sows and the foetal tis-
sue also underwent an extensive microbiologi-
cal screening. In eight patients, the tissue was
injected to the liver via the portal vein. In four
of these patients, function of the pancreatic tis-
sue was observed for a maximum of 450 days as
measured by excretion of porcine C-peptide in
urine. In the last two patients the porcine grafts
were injected under the capsule of a simultane-
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ously transplanted human kidney. Surviving pig
cells were then found in a kidney graft biopsy
taken three weeks after transplantation. The
finding was remarkable as this was the first time
pig tissue was shown to survive in a human be-
ing. In no case, however, could the patients stop
their insulin injections. The postoperative
courses were uneventful, and there were no
signs of infectious complications.
In the United States, a biotech company has
performed transplantations of foetal pig neu-
rons to treat patients with Parkinson's disease,
Huntington's disease, and in a few cases,
epilepsy or sequel after stroke (4). In the pilot
study on Parkinson's disease, several patients
reported remarkable improvements. The treat-
ment has since then been analysed in a ran-
domised placebo-controlled trial. Survival of
the cellular graft occurred in several patients.
However, no clear therapeutic effect was noted
in the controlled trial. 
Bovine adrenal cells have also been evaluated
as treatment for patients with morphine-resis-
tant cancer pain (3). The cells were placed in a
semi-permeable membrane, and put into the
spinal canal. No immunosuppressives were
given in this study. The cells were protected by
the membrane, and by being placed behind the
blood-brain barrier where the immunological
response is weaker than in the rest of the body.
Secretion of therapeutic substances, and sur-
vival of cells for more than six months, were
observed, but the therapeutic effect was ques-
tionable. In Switzerland, xenotransplantation
has been attempted as a treatment for amy-
otrophic lateral sclerosis (ALS) (11). In this
study, baby hamster cells were genetically mod-
ified to secrete a human neurotrophic factor.
Encapsulated cells were placed in the spinal
canal, and again secretion of the therapeutic
protein was observed, and cells survived for
several months even without immunosuppres-
sion.
Xenotransplantation is usually defined as any
contact between a human patient's body fluids
and animal organs or tissue. Using this defini-
tion several hundreds of patients in both Europe
and the United States have been "xenotrans-
planted"  when treated with a bioartificial liver.
Most patients suffered from acute liver failure,
and the treatment was an attempt to keep the pa-
tients alive until a human graft for transplanta-
tion became available. Their plasma was passed
through a "liver dialysis machine" containing
encapsulated pig cells (6). Improvements in
hepatic encephalopathy and certain biochemi-
cal parameters have been observed. 
Regulatory development
The scientific development of xenotransplanta-
tion during the 1990's led to several national
and international initiatives to regulate the clin-
ical use of the procedure. The main concern
was the risk for infectious complications, af-
fecting not only the patient, but also potentially
introducing new pathogens into the general
population. Two land-mark reports were pub-
lished in the United Kingdom. The first was
produced by the Nuffield Council on Bioethics
(13) and was within a year followed by a gov-
ernmental report "Animal tissue into humans –
a report from the advisory group on the ethics
on xenotransplantation" (14). The ethical basis
for these reports is the traditional weighing of
benefits against risks. They conclude that the
scientific basis at that time was insufficient for
entering clinical trials. The term source animal
is recommended instead of donor as the ani-
mals obviously do not donate their organs. Pig
is considered acceptable as source animals
while non-human primates are not considered
acceptable for the reasons given earlier in this
article. The production of transgenic pigs is
also considered acceptable as long as the pigs
"remain pigs", and are not caused to suffer from
the genetic modification. The potential infec-
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tious risk for the public is emphasised and con-
sidered as a major area for further investiga-
tions. The importance of education of and ex-
tensive information to future xenograft
recipients and their families to make it possible
to obtain a truly informed consent is under-
lined. The reports led to the foundation of the
United Kingdom Xenotransplantation Interim
Regulatory Authority (UKXIRA). The
UKXIRA has produced a number of reports
within the field, which can be found on their
web site. The UKXIRA has set high standards
for approving a clinical xenotransplantation
trial, and so far, they have not received any ap-
plications. 
The regulatory development in the rest of Eu-
rope varies (9). Some countries have decided
on, or are considering a moratorium for clinical
xenotransplantation e.g. Switzerland and The
Netherlands. Others, such as the UK and Spain,
have issued reports suggesting a regulatory
framework within which applications for xeno-
transplantation trials could be considered.
Among the Nordic countries, Norway and Den-
mark at present have moratoriums for clinical
xenotransplantation trials, while Finland and
Iceland have no official stand on the subject. In
Sweden, a governmental report has suggested a
legal framework making it possible to perform
limited trials, but the report has not yet been
presented to the Parliament.  
The United States authorities have taken a more
liberal standpoint to clinical xenotransplanta-
tion trials. Several studies on cellular xeno-
transplantation have been approved. They are
performed within a strict regulatory framework
and extensive microbiological testing and fol-
low-up are required (2). Samples from source
animals and recipients are to be stored for 50
years. A central registry of xenotransplant re-
cipients and a central archive for the safety
samples is being developed. Applications are
handled by the Food and Drug Administration,
and a number of reports and recommendations
on clinical xenotransplantation trials can be
found on the FDA web site. As in the UK, pri-
mates are not considered acceptable as source
animals.
The infectious risks connected with xenotrans-
plantation were highlighted a few years ago, but
more data are now available, and most experts
in the field today agree that the risk to the pub-
lic is minimal provided that strict safety pre-
cautions are followed. Obviously, microbes do
not respect geographical borders, and countries
having a moratorium on clinical xenotransplan-
tation, may still have to face the effects of trials
performed elsewhere. With this background,
several international organisations, including
the WHO (12) and the OECD have organised
workshops and published reports in the field.
The European Council has also appointed a
working group producing a state of the art re-
port and draft guidelines for clinical xenotrans-
plantation trials. The international perspective
is also important to prevent so-called xeno-
tourism. This term refers both to patients trav-
elling to countries were the treatment is offered,
but lacking proper follow-up at home, and to
companies or researchers having applications
turned down in their own country and will then
perform xenotransplantations in countries lack-
ing regulatory framework and the resources to
control the trials. The international regulatory
initiatives will hopefully provide all countries
with baseline recommendations for clinical
xenografting and promote rapid exchange of
experiences across borders.   
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